Dapagliflozin, a SGLT2 inhibitor, has been reported to decrease blood glucose concentrations and through upregulation of insulin and GLP-1 levels in T2DM mice, exhibit protective effects on the β-cells and enhanced β-cell replication [133]. Here, GLP1R is linked to type 2 diabetes mellitus.